FLGT RSI Chart
Last 7 days
-1.3%
Last 30 days
-14.1%
Last 90 days
-27.8%
Trailing 12 Months
-29.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 364.9M | 307.4M | 286.4M | 289.2M |
2022 | 953.4M | 869.8M | 702.6M | 619.0M |
2021 | 773.4M | 909.7M | 1.0B | 992.6M |
2020 | 34.9M | 43.8M | 135.1M | 421.7M |
2019 | 22.1M | 25.1M | 29.8M | 32.5M |
2018 | 18.1M | 18.8M | 20.0M | 21.4M |
2017 | 20.1M | 20.8M | 20.3M | 18.7M |
2016 | 11.4M | 13.2M | 15.3M | 18.3M |
2015 | 3.4M | 5.4M | 7.5M | 9.6M |
2014 | 0 | 0 | 0 | 1.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 01, 2024 | kim paul | sold (taxes) | -36,091 | 23.24 | -1,553 | cfo and treasurer |
Mar 01, 2024 | gao hanlin | sold (taxes) | -22,589 | 23.24 | -972 | chief scientific officer |
Mar 01, 2024 | xie jian | sold (taxes) | -34,372 | 23.24 | -1,479 | president and coo |
Feb 26, 2024 | xie jian | acquired | - | - | 35,636 | president and coo |
Feb 26, 2024 | xie jian | sold (taxes) | -134,134 | 24.26 | -5,529 | president and coo |
Feb 26, 2024 | hsieh ming | sold (taxes) | -437,893 | 24.26 | -18,050 | chief executive officer |
Feb 26, 2024 | kim paul | acquired | - | - | 34,862 | cfo and treasurer |
Feb 26, 2024 | hsieh ming | acquired | - | - | 99,721 | chief executive officer |
Feb 26, 2024 | gao hanlin | sold (taxes) | -79,815 | 24.26 | -3,290 | chief scientific officer |
Feb 26, 2024 | gao hanlin | acquired | - | - | 30,377 | chief scientific officer |
Which funds bought or sold FLGT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -83.36 | -54,561 | 11,969 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.61 | 3,674,250 | 40,942,100 | -% |
Mar 05, 2024 | Fisher Asset Management, LLC | sold off | -100 | -12,861 | - | -% |
Mar 04, 2024 | VIMA LLC | new | - | 3,469 | 3,469 | 0.01% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 97.51 | 3,148,470 | 5,921,460 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.91 | 21,409 | 321,566 | -% |
Feb 27, 2024 | Beaird Harris Wealth Management, LLC | unchanged | - | 32.00 | 434 | -% |
Feb 26, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 15,000 | 186,000 | -% |
Feb 20, 2024 | Aurora Investment Counsel | sold off | -100 | -222,263 | - | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 15.48 | 62,000 | 313,000 | -% |
Unveiling Fulgent Genetics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Peers (Alternatives to Fulgent Genetics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 184.1B | 23.9B | 38.82 | 7.71 | ||||
IDXX | 44.8B | 3.7B | 53.05 | 12.25 | ||||
A | 43.2B | 6.7B | 34.96 | 6.42 | ||||
DGX | 14.5B | 9.3B | 16.99 | 1.57 | ||||
CRL | 13.8B | 4.1B | 29.14 | 3.35 | ||||
MEDP | 12.4B | 1.9B | 43.86 | 6.58 | ||||
EXAS | 12.1B | 2.5B | -59.47 | 4.86 | ||||
NTRA | 10.9B | 1.1B | -25.12 | 10.09 | ||||
MID-CAP | ||||||||
NEOG | 3.3B | 918.7M | 284.21 | 3.64 | ||||
GH | 2.2B | 563.9M | -4.56 | 3.88 | ||||
SMALL-CAP | ||||||||
CDNA | 544.7M | 280.3M | -2.86 | 1.94 | ||||
ACRS | 89.4M | 31.2M | -1.01 | 2.86 | ||||
AWH | 35.6M | 9.2M | -1.95 | 3.87 | ||||
APDN | 7.6M | 9.0M | -1.06 | 0.85 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Fulgent Genetics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -16.7% | 70,505 | 84,687 | 67,853 | 66,168 | 67,704 | 105,655 | 125,341 | 222,805 | 320,268 | 251,671 | 227,868 | 153,616 | 359,429 | 294,978 | 101,716 | 17,265 | 7,753 | 8,387 | 10,347 | 8,424 | 5,370 |
Cost Of Revenue | 1.0% | 45,276 | 44,843 | 47,281 | 47,357 | 54,717 | 59,560 | 60,065 | - | 77,725 | 62,134 | 43,466 | 35,858 | 74,075 | 51,772 | 26,261 | 7,717 | 4,057 | 3,634 | 3,885 | 3,620 | 2,968 |
Gross Profit | -36.7% | 25,229 | 39,844 | 20,572 | 18,811 | 12,987 | 46,095 | 65,276 | - | 242,543 | 189,537 | 184,402 | 117,758 | 285,354 | 243,206 | 75,455 | 9,548 | 3,696 | 4,753 | 6,462 | 4,804 | 2,402 |
Operating Expenses | 345.0% | 176,350 | 39,630 | 40,370 | 43,635 | 49,539 | 45,743 | 52,482 | - | 40,610 | 38,677 | 25,129 | 18,860 | 18,432 | 17,297 | 11,932 | 6,908 | 5,610 | 5,162 | 4,953 | 4,509 | 4,225 |
S&GA Expenses | 3.3% | 10,500 | 10,161 | 10,723 | 10,083 | 10,253 | 9,859 | 10,866 | - | 7,940 | 8,200 | 6,012 | 5,219 | 5,008 | 5,081 | 5,014 | 3,260 | 1,597 | 1,635 | 1,687 | 1,304 | 1,272 |
R&D Expenses | 19.4% | 11,952 | 10,014 | 9,692 | 9,782 | 8,509 | 7,507 | 6,905 | - | 5,989 | 7,464 | 6,021 | 5,312 | 5,422 | 4,576 | 3,177 | 1,849 | 1,978 | 1,795 | 1,744 | 1,574 | 1,424 |
EBITDA Margin | -Infinity% | -0.51* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | -153.4% | -10,859 | 20,326 | -3,100 | -5,200 | -9,386 | 414 | 2,653 | - | 48,400 | 47,148 | 37,545 | 23,589 | 66,513 | 58,571 | 14,526 | -599 | 34.00 | -38.00 | 61.00 | 7.00 | 13.00 |
Earnings Before Taxes | -2216.6% | -145,196 | 6,860 | -14,700 | -21,049 | -33,462 | 1,757 | 13,752 | - | 201,978 | 150,825 | 159,769 | 99,502 | 267,204 | 226,498 | 63,944 | 2,915 | -1,673 | -160 | 1,698 | 487 | -1,616 |
EBT Margin | -176.5% | -0.60* | -0.22* | -0.22* | -0.11* | 0.30* | 0.52* | 0.67* | 0.70* | 0.64* | 0.68* | 0.73* | 0.72* | - | - | - | - | - | - | - | - | - |
Net Income | -874.4% | -127,714 | -13,107 | -11,590 | -15,849 | -23,832 | 1,719 | 11,099 | - | 153,557 | 104,339 | 122,522 | 79,812 | 200,691 | 166,307 | 46,638 | 3,321 | -1,956 | -296 | 1,462 | 331 | -1,908 |
Net Income Margin | -158.8% | -0.58* | -0.22* | -0.16* | -0.07* | 0.23* | 0.39* | 0.50* | 0.53* | 0.48* | 0.51* | 0.55* | 0.54* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 122.4% | 11,827 | 5,317 | -2,407 | -9,941 | 28,485 | 15,341 | 7,868 | 183,051 | 183,051 | 71,103 | 148,799 | 73,176 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -9.1% | 1,235 | 1,358 | 1,355 | 1,377 | 1,386 | 1,406 | 1,462 | 1,466 | 1,279 | 1,205 | 1,050 | 999 | 700 | 247 | 96.00 | 89.00 | 89.00 | 61.00 | 56.00 | 56.00 | 54.00 |
Current Assets | -7.6% | 508 | 550 | 528 | 581 | 628 | 697 | 675 | 765 | 612 | 623 | 567 | 659 | 524 | 196 | 41.00 | 37.00 | 37.00 | 39.00 | 35.00 | 36.00 | 40.00 |
Cash Equivalents | 15.9% | 97.00 | 84.00 | 58.00 | 66.00 | 80.00 | 169 | 139 | 353 | 165 | 215 | 100 | 151 | 87.00 | 53.00 | 2.00 | 9.00 | 12.00 | 21.00 | 9.00 | 5.00 | 7.00 |
Net PPE | -2.1% | 83.00 | 85.00 | 88.00 | 79.00 | 81.00 | 82.00 | 86.00 | 69.00 | 62.00 | 60.00 | 51.00 | 47.00 | 40.00 | 17.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 |
Goodwill | -84.5% | 22.00 | 142 | 142 | 143 | 143 | 120 | 121 | 51.00 | 51.00 | 49.00 | 23.00 | - | - | - | - | - | - | - | - | - | - |
Liabilities | 5.7% | 102 | 97.00 | 91.00 | 108 | 116 | 124 | 151 | 153 | 113 | 160 | 129 | 198 | 131 | 60.00 | 9.00 | 8.00 | 6.00 | 7.00 | 5.00 | 6.00 | 3.00 |
Current Liabilities | 18.9% | 73.00 | 61.00 | 65.00 | 82.00 | 88.00 | 103 | 128 | 142 | 105 | 147 | 122 | 197 | 130 | 58.00 | 7.00 | 6.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Shareholder's Equity | -9.7% | 1,136 | 1,259 | 1,263 | 1,269 | 1,267 | 1,281 | 1,311 | 1,313 | 1,166 | 1,044 | 921 | 802 | 569 | 187 | 87.00 | 81.00 | 83.00 | 55.00 | 51.00 | 50.00 | 51.00 |
Retained Earnings | -16.8% | 633 | 761 | 774 | 786 | 801 | 825 | 823 | 812 | 658 | 553 | 431 | 351 | 151 | -15.43 | -62.06 | -65.39 | -63.43 | -63.13 | -64.59 | -64.93 | -63.02 |
Additional Paid-In Capital | -2.4% | 502 | 514 | 506 | 496 | 487 | 478 | 504 | 507 | 502 | 484 | 482 | 451 | 418 | 202 | 148 | 147 | 146 | 117 | 116 | 115 | 114 |
Shares Outstanding | -1.3% | 30.00 | 30.00 | 30.00 | 30.00 | 29.00 | 30.00 | 30.00 | 30.00 | 29.00 | 30.00 | 29.00 | - | - | - | - | - | - | - | - | - | - |
Minority Interest | -189.8% | -2.81 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 6.00 | 7.00 | 7.00 | 8.00 | 8.00 | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 629 | - | - | - | 978 | - | - | - | 1,600 | - | - | - | 191 | - | - | - | 39.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 45.8% | 14,933 | 10,240 | 9,737 | -7,907 | 33,207 | 20,776 | 11,126 | 188,411 | 77,086 | 152,201 | 76,111 | 233,179 | 134,256 | 9,415 | -4,409 | 1,366 | -116 | 3,903 | 675 | 1,055 | 778 |
Share Based Compensation | 4.9% | 11,432 | 10,902 | 10,323 | 10,265 | 10,022 | 8,972 | 8,030 | 5,616 | 5,020 | 4,374 | 3,526 | 2,962 | 3,003 | 3,150 | 1,080 | 924 | 938 | 951 | 737 | 583 | 598 |
Cashflow From Investing | 20.9% | 24,270 | 20,078 | -1,096 | -4,354 | -92,599 | 44,289 | -213,692 | 688 | -140,259 | -34,793 | -155,005 | -216,491 | -318,767 | -1,404 | -2,405 | -3,862 | -36,079 | 6,344 | 3,211 | -2,522 | -2,536 |
Cashflow From Financing | -480.0% | -25,951 | -4,474 | -16,259 | -1,101 | -29,593 | -35,462 | -11,152 | -934 | 13,154 | -2,989 | 27,893 | 47,347 | 218,903 | 42,571 | -59.00 | -164 | 27,639 | 1,127 | 5.00 | 4.00 | 5.00 |
Buy Backs | 940.1% | 22,862 | 2,198 | - | - | 28,803 | 34,700 | 10,577 | - | - | - | - | 513 | 16.00 | - | - | 46.00 | - | - | - | - | - |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Revenue | $ 289,213 | $ 618,968 | $ 992,584 |
Cost of revenue | 184,757 | 252,067 | 215,533 |
Gross profit | 104,456 | 366,901 | 777,051 |
Operating expenses: | |||
Research and development | 41,440 | 28,910 | 24,219 |
Selling and marketing | 41,467 | 38,918 | 24,439 |
General and administrative | 88,999 | 111,074 | 50,732 |
Amortization of intangible assets | 7,845 | 6,497 | 1,708 |
Goodwill impairment loss | 120,234 | ||
Restructuring costs | 2,975 | ||
Total operating expenses | 299,985 | 188,374 | 101,098 |
Operating (loss) income | (195,529) | 178,527 | 675,953 |
Interest and other income, net | 21,444 | 5,498 | 1,347 |
(Loss) income before income taxes and gain on equity-method investments | (174,085) | 184,025 | 677,300 |
Provision for income taxes | 1,154 | 42,102 | 174,795 |
(Loss) income before gain on equity-method investments | (175,239) | 141,923 | 502,505 |
Gain on equity-method investments | 3,734 | ||
Net (loss) income from consolidated operations | (175,239) | 141,923 | 506,239 |
Net loss attributable to noncontrolling interests | 7,414 | 1,480 | 1,125 |
Net (loss) income attributable to Fulgent | $ (167,825) | $ 143,403 | $ 507,364 |
Net (loss) income per common share attributable to Fulgent: | |||
Basic | $ (5.63) | $ 4.76 | $ 17.25 |
Diluted | $ (5.63) | $ 4.63 | $ 16.38 |
Weighted-average common shares: | |||
Basic | 29,784 | 30,097 | 29,408 |
Diluted | 29,784 | 30,964 | 30,976 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 97,473 | $ 79,506 |
Marketable securities | 326,681 | 446,729 |
Trade accounts receivable, net of allowance for credit losses of $25,226 and $41,205 | 51,132 | 52,749 |
Other current assets | 32,559 | 48,889 |
Total current assets | 507,845 | 627,873 |
Marketable securities, long-term | 423,571 | 326,648 |
Redeemable preferred stock investment | 20,438 | 12,385 |
Fixed assets, net | 83,464 | 81,353 |
Intangible assets, net | 143,053 | 150,643 |
Goodwill, net | 22,055 | 143,027 |
Other long-term assets | 34,902 | 44,124 |
Total assets | 1,235,328 | 1,386,053 |
Current liabilities | ||
Accounts payable | 15,360 | 23,093 |
Accrued liabilities | 30,737 | 24,981 |
Contract liabilities | 2,874 | 3,199 |
Customer deposit | 22,700 | 10,895 |
Investment margin loan | 14,999 | |
Notes payable, current portion | 1,183 | 5,639 |
Other current liabilities | 164 | 5,301 |
Total current liabilities | 73,018 | 88,107 |
Unrecognized tax benefits | 5,978 | 9,836 |
Deferred tax liabilities | 7,962 | |
Other long-term liabilities | 15,084 | 18,235 |
Total liabilities | 102,042 | 116,178 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity | ||
Common stock, $0.0001 par value per share, 50,000 shares authorized, 32,416 shares issued and 29,653 shares outstanding and 31,248 shares issued and 29,438 shares outstanding | 3 | 3 |
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding | ||
Additional paid-in capital | 501,718 | 486,585 |
Accumulated other comprehensive income (loss) | 1,205 | (20,903) |
Retained earnings | 633,175 | 801,000 |
Total Fulgent stockholders' equity | 1,136,101 | 1,266,685 |
Noncontrolling interest | (2,815) | 3,190 |
Total stockholders’ equity | 1,133,286 | 1,269,875 |
Total liabilities and stockholders’ equity | $ 1,235,328 | $ 1,386,053 |
 | Mr. Ming Hsieh |
---|---|
 | www.fulgentgenetics.com |
 | 1012 |